ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $241,208,570 | -10.2% | 8,887,567 | +1.7% | 0.03% | -6.9% |
Q2 2023 | $268,549,912 | -14.0% | 8,736,171 | +0.7% | 0.03% | -23.7% |
Q1 2023 | $312,436,000 | +93739.6% | 8,671,563 | +2.9% | 0.04% | -13.6% |
Q4 2022 | $332,947 | -99.9% | 8,424,747 | +1.1% | 0.04% | -8.3% |
Q3 2022 | $334,764,000 | +4.1% | 8,331,597 | +8.9% | 0.05% | +6.7% |
Q2 2022 | $321,522,000 | +48.4% | 7,647,985 | +37.6% | 0.04% | +73.1% |
Q1 2022 | $216,592,000 | +0.2% | 5,559,388 | +2.5% | 0.03% | +4.0% |
Q4 2021 | $216,075,000 | +12.5% | 5,422,203 | +2.0% | 0.02% | +4.2% |
Q3 2021 | $192,138,000 | -35.9% | 5,316,482 | -27.3% | 0.02% | -33.3% |
Q2 2021 | $299,842,000 | +18.6% | 7,315,001 | +26.2% | 0.04% | +5.9% |
Q1 2021 | $252,790,000 | -16.9% | 5,795,267 | -4.7% | 0.03% | -24.4% |
Q4 2020 | $304,322,000 | +93.1% | 6,080,359 | +62.1% | 0.04% | +73.1% |
Q3 2020 | $157,590,000 | -12.8% | 3,751,236 | +0.7% | 0.03% | -25.7% |
Q2 2020 | $180,797,000 | – | 3,723,924 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |